Sarepta Therapeutics (SRPT) Income towards Parent Company (2010 - 2026)
Sarepta Therapeutics' quarterly Income towards Parent Company came in at $331.0 million in Q1 2026, up 173.96% year-on-year from $120.8 million in Q1 2025, and up 216.86% quarter-over-quarter from -$283.2 million in Q4 2025.
Sarepta Therapeutics has reported Income towards Parent Company for 17 years, with the latest figure at $331.0 million in Q1 2026.
- For the quarter ending Q1 2026, Income towards Parent Company rose 173.96% year-over-year to $331.0 million; the trailing twelve-month figure through Mar 2026 stood at $64.7 million (up 118.99% YoY), and the FY2025 full-year result was -$713.8 million, down 599.55% from the prior year.
- Income towards Parent Company for Q1 2026 stood at $331.0 million, up from -$283.2 million in the prior quarter.
- The five-year high for Income towards Parent Company was $331.0 million in Q1 2026, with the low at -$516.8 million in Q1 2023.
- Average Income towards Parent Company over 5 years is -$46.5 million, with a median of -$23.9 million recorded in 2023.
- Peak annual rise in Income towards Parent Company reached 2939.86% in 2025, while the deepest fall reached 1337.99% in 2025.
- Tracing SRPT's Income towards Parent Company over 5 years: stood at $329.3 million in 2022, then slipped by 10.11% to $296.1 million in 2023, then tumbled by 77.47% to $66.7 million in 2024, then sank by 524.65% to -$283.2 million in 2025, then surged by 216.86% to $331.0 million in 2026.
- The last three Income towards Parent Company figures came in at $331.0 million (Q1 2026), -$283.2 million (Q4 2025), and -$179.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Sarepta Therapeutics | 1.86 Bn | 1.17 Bn | 291.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 330.96 Mn |
| Dec 31, 2025 | -283.21 Mn |
| Sep 30, 2025 | -179.95 Mn |
| Jun 30, 2025 | 196.89 Mn |
| Mar 31, 2025 | -447.51 Mn |
| Dec 31, 2024 | 66.69 Mn |
| Sep 30, 2024 | 33.61 Mn |
| Jun 30, 2024 | 6.48 Mn |
| Mar 31, 2024 | 36.15 Mn |
| Dec 31, 2023 | 296.05 Mn |
| Sep 30, 2023 | -40.94 Mn |
| Jun 30, 2023 | -23.94 Mn |
| Mar 31, 2023 | -516.76 Mn |
| Dec 31, 2022 | 329.34 Mn |
| Sep 30, 2022 | -257.74 Mn |
| Jun 30, 2022 | -231.48 Mn |
| Mar 31, 2022 | -105.03 Mn |
| Dec 31, 2021 | -74.35 Mn |
| Sep 30, 2021 | -48.14 Mn |
| Jun 30, 2021 | -81.41 Mn |
| Mar 31, 2021 | -167.25 Mn |
| Dec 31, 2020 | -189.32 Mn |
| Sep 30, 2020 | -196.50 Mn |
| Jun 30, 2020 | -150.82 Mn |
| Mar 31, 2020 | -17.49 Mn |
| Dec 31, 2019 | -235.70 Mn |
| Sep 30, 2019 | -126.33 Mn |
| Jun 30, 2019 | -276.40 Mn |
| Mar 31, 2019 | -76.64 Mn |
| Dec 31, 2018 | -140.90 Mn |
| Sep 30, 2018 | -76.39 Mn |
| Jun 30, 2018 | -109.27 Mn |
| Mar 31, 2018 | -35.36 Mn |
| Dec 31, 2017 | -24.00 Mn |
| Sep 30, 2017 | -47.73 Mn |
| Jun 30, 2017 | -63.05 Mn |
| Mar 31, 2017 | 84.09 Mn |
| Dec 31, 2016 | -88.45 Mn |
| Sep 30, 2016 | -56.74 Mn |
| Jun 30, 2016 | -62.30 Mn |
| Mar 31, 2016 | -59.77 Mn |
| Dec 31, 2015 | -64.45 Mn |
| Sep 30, 2015 | -51.76 Mn |
| Jun 30, 2015 | -42.11 Mn |
| Mar 31, 2015 | -61.86 Mn |
| Dec 31, 2014 | -44.72 Mn |
| Sep 30, 2014 | -33.68 Mn |
| Jun 30, 2014 | -30.27 Mn |
| Mar 31, 2014 | -25.12 Mn |
| Dec 31, 2013 | -32.85 Mn |
| Sep 30, 2013 | -24.87 Mn |
| Jun 30, 2013 | -17.11 Mn |
| Mar 31, 2013 | -15.18 Mn |
| Dec 31, 2012 | -10.28 Mn |
| Sep 30, 2012 | -6.84 Mn |
| Jun 30, 2012 | -5.45 Mn |
| Mar 31, 2012 | -6.78 Mn |
| Dec 31, 2011 | -8.85 Mn |
| Sep 30, 2011 | -11.07 Mn |
| Jun 30, 2011 | -9.97 Mn |
| Mar 31, 2011 | -5.44 Mn |
| Dec 31, 2010 | -1.65 Mn |
| Sep 30, 2010 | -3.72 Mn |
| Jun 30, 2010 | -7.62 Mn |